The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer

References

• Belldegrun AS, Franklin JR, O'Donnell MA, Gomella LG, Klein E, Neri R, . Superficial bladder cancer: The role of interferon-alpha. J Urol 1998;159:1793–801.
   PubMed Web of Science ®Google Scholar
• Nawrocki S, Skacel T, Skoneczna I. Pharmacotherapy of bladder cancer – practice and prospects. Expert Opin Pharmacother 2002;3:671–9.
   PubMedGoogle Scholar
• Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005;11:8816–21.
   PubMed Web of Science ®Google Scholar
• Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 1997;8:1935–43.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 1999;10: 1375–87.
   PubMed Web of Science ®Google Scholar
• Dzojic H, Loskog A, Totterman TH, Essand M. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 2006;66:831–8.
   PubMed Web of Science ®Google Scholar
• Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152–72.
   PubMed Web of Science ®Google Scholar
• van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, . CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002;99:5561–6.
   PubMed Web of Science ®Google Scholar
• Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: Across the great divide. Immunol Today 1998;19:502–6.
   PubMedGoogle Scholar
• Hess S, Engelmann H. A novel function of CD40: Induction of cell death in transformed cells. J Exp Med 1996;183: 159–67.
   PubMed Web of Science ®Google Scholar
• Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, . Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001;7:691–703.
   PubMed Web of Science ®Google Scholar
• Yamada M, Shiroko T, Kawaguchi Y, Sugiyama Y, Egilmez NK, Chen FA, . CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors. Int J Cancer 2001;92:589–99.
   PubMed Web of Science ®Google Scholar
• Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S, . A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction. J Exp Med 1997;185:2053–60.
   PubMed Web of Science ®Google Scholar
• Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152–72.
   PubMed Web of Science ®Google Scholar
• Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, . Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995;270: 7025–8.
   PubMed Web of Science ®Google Scholar
• Morris AE, Jr Remmele RL, Klinke R, Macduff BM, Fanslow WC, Armitage RJ. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem 1999;274:418–23.
   PubMed Web of Science ®Google Scholar
• Sano T, Cantor CR. Streptavidin-containing chimeric proteins: Design and production. Methods Enzymol 2000;326: 305–11.
   PubMed Web of Science ®Google Scholar
• Gao J, Huang S, Li M, Luo R, Wang X, Takashima A. GM-CSF-surface-modified B16.F10 melanoma cell vaccine. Vaccine 2006;24:5265–8.
   PubMed Web of Science ®Google Scholar
• Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmstrom PU, Totterman TH. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim 2005;39:384–93.
   PubMed Web of Science ®Google Scholar
• Hu Z, Tan W, Zhang L, Liang Z, Xu C, Su H, . A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF. J Cell Mol Med 2010; 14:1836–44.
   PubMed Web of Science ®Google Scholar